Kidney Transplant Articles & Analysis
36 news found
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
ByBayer AG
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. ...
ByBayer AG
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D. ...
ByBayer AG
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D. ...
ByBayer AG
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D. ...
ByBayer AG
These data were shared today in an oral plenary presentation at the American Transplant Congress (ATC) in Boston (Abstract 387). “Kidney transplant recipients are particularly challenged by BK viremia, which puts the survival of their transplanted graft at risk,” said Anil K. ...
ByKalaris
“A treatment response meeting these proteinuria treatment targets increases the chance for better long-term kidney outcomes such as avoidance of kidney failure, dialysis or need for ...
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed ...
Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients Progressed enrollment in three Phase 3 studies for ...
ByKalaris
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediatric patients following allogeneic hematopoietic cell ...
ByKalaris
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D. ...
ByBayer AG
“I look forward to the dosing of more patients and seeing data from the study to understand the potential of TX200.” Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD) who must otherwise remain on long-term dialysis. Approximately 21-26% of transplanted kidneys are ...
The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in eGFR, the onset of end-stage kidney disease (i.e., maintenance dialysis for ≥28 days, kidney transplantation or a sustained eGFR of2) or death. ...
Ischemic reperfusion injury is a common occurrence during organ transplantation. Although such a problem is less common with living transplants, brain-dead transplants are prone to tissue damage and inflammation due to free radicals due to the time the organs are transported. CEO Kim said, “Even though organ transplantation ...
“The worrying reality is that chronic kidney disease in type 2 diabetes is the leading cause of end-stage kidney disease, which ultimately means that the kidneys no longer support the body’s needs and patients need dialysis or a kidney transplant to stay alive. ...
ByBayer AG
A July 2019 White House executive order on kidney care (the Advancing American Kidney Health Initiative) proposed that 80% of new patients with end-stage renal disease (ESRD) be treated with either kidney transplantation or home dialysis by 2025, a significant increase from current rates, which are below 20%. ...
Following a review at the end of last year of initial, blinded safety data from the ongoing posoleucel proof-of-concept (POC) study for BK viremia treatment in adult kidney transplant recipients, the study has been amended to begin enrolling patients with higher viral loads. BKV is detected in up to 20% of kidney transplant ...
ByKalaris
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical ...